Lung cancer trials in Germany

In Germany 183 Also abroad 2729

183 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 2Not yet taking people in Germany
An international study evaluating diagnostic and theranostic agents in patients with solid tumors and brain metastases.
Where
Munich
Age
18 years and over
People
20
Run by
Medica Scientia Innovation Research S.L.
See details and how to join2025-523824-39-01 · EU 2025-523824-39-01
Phase 3Not yet taking people in Germany
A Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC
Where
Bonn, Giessen, Luebeck, Munich
Age
18 years and over
People
95 worldwide
Run by
Summit Therapeutics Inc.
See details and how to join2026-526300-67-00 · EU 2026-526300-67-00
Phase 1Taking people
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Where
Berlin, Frankfurt am Main, Goettingen, Heidelberg, Tübingen
Age
18 years and over
People
15 worldwide
Run by
Valo Therapeutics Oy
See details and how to joinNCT05492682 · EU 2024-517580-23-00
Phase 3Taking people
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Where
Berlin, Bonn, Chemnitz, Dortmund, Essen, Esslingen am Neckar, Gauting, Grosshansdorf, Hannover, Herne, Kempten (Allgau), Luebeck, Marburg, Muenster, Munich, Ulm
Age
18 years and over
People
1,000 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01
Phase 3Taking people
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Where
Eschweiler, Giessen, Heidelberg, Kempten (Allgau), Mainz, Muenster, Oldenburg, Stuttgart
Age
18 years and over
People
680 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00
No phaseTaking people
General Anesthesia vs Conscious Sedation for Radial Endobronchial Ultrasound
Where
Frankfurt am Main
Age
18 years and over
People
306 worldwide
Run by
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
See details and how to joinNCT06950515
Phase 1/2Taking people
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Where
Cologne, Jena, Tuebingen, Wuerzburg
Age
18 years to 64 years
People
170 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07227597 · EU 2025-521032-11-00
Phase 2Taking people
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Where
Cologne, Heidelberg
Age
18 years and over
People
60 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07486817 · EU 2025-523567-38-00
Phase 3Taking people
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Where
Berlin, Bochum, Essen, Gera, Grosshansdorf, Heidelberg, Mainz, Regensburg
Age
18 years and over
People
876 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Where
Berlin, Bielefeld, Essen, Esslingen am Neckar, Gauting, Homburg, Offenbach Am Main, Oldenburg, Regensburg, Stuttgart, Wuerzburg
Age
18 years and over
People
400 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01
Phase 3Taking people
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Where
Berlin, Brunswick, Cologne, Dresden, Frankfurt am Main, Gauting, Grosshansdorf, Hamburg, Homburg, Jena, Oldenburg, Stuttgart
Age
18 years and over
People
356 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566052 · EU 2025-524079-22-00
Phase 1/2Taking people
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Where
Cologne, Frankfurt Am Main, Grosshansdorf, Heidelberg
Age
12 years and over
People
840 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00
Phase 3Taking people
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Where
Chemnitz, Gauting, Goettingen, Immenstadt I. Allgäu, Munich
Age
18 years to 100 years
People
750 worldwide
Run by
Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00
Phase 3Taking people
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Where
Berlin, Dresden, Essen, Esslingen am Neckar, Gauting, Giessen, Goettingen, Heidelberg, Immenhausen, Köln, Luebeck, Munich
Age
18 years and over
People
590 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06881784 · EU 2024-518154-16-00
Phase 2Taking people
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Where
Chemnitz, Essen, Esslingen am Neckar, Munich
Age
18 years and over
People
105 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT07659782 · EU 2026-526472-23-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Berlin, Dresden, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Halle, Hamburg, Hanover, Heidelberg, Homburg, Immenhausen, Karlsruhe, Löwenstein, Lübeck, Mannheim, München, Münster, Oldenburg, Regensburg, Tübingen, Würzburg
Age
18 years and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Bad Berka, Berlin, Bonn, Essen, Frankfurt am Main, Gauting, Giessen, Grosshansdorf, Heidelberg, Homburg, Hösbach, Immenhausen, Jena, Kassel, Koblenz, Luebeck, Moers, Stuttgart
Age
18 years and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
Phase 3Taking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Augsburg, Berlin, Gauting, Goettingen, Grosshansdorf, Halle (saale), Immenhausen, Jena, Koblenz, Ludwigshafen Am Rhein, Luebeck, Regensburg
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
Phase 1/2Taking people
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Where
Cologne, Essen, Frankfurt Am Main, Heidelberg, Oldenburg
Age
18 years and over
People
160 worldwide
Run by
TRIANA Biomedicines, Inc.
See details and how to joinNCT07491497 · EU 2025-524418-27-00
Phase 3Taking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Berlin, Chemnitz, Cologne, Donauwörth, Erfurt, Freiburg im Breisgau, Gauting, Georgsmarienhütte, Gera, Grosshansdorf, Halle (Saale), Hamburg, Heidelberg, Kiel, Muenster, Nuremberg, Tuebingen
Age
18 years and over
People
1,264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
Phase 3Taking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Berlin, Cologne, Essen, Frankfurt Am Main, Giessen, Hemer, Nuremberg, Stuttgart
Age
18 years and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
Phase 1Taking people
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Where
Berlin, Essen, Frankfurt am Main
Age
18 years and over
People
340 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06561685 · EU 2024-519727-18-00
Phase 3Taking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Berlin, Chemnitz, Cologne, Erfurt, Gauting, Georgsmarienhütte, Großhansdorf, Halle, Hamburg, Heidelberg, Hemer, Herne, Leipzig, Nuremberg, Stuttgart, Tübingen
Age
18 years and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Hamburg, Heidelberg, Leipzig, Mainz, München, Würzburg
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
Phase 3Taking people
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Where
Berlin, Gauting, Georgsmarienhuette, Heidelberg, Mainz, Oldenburg
Age
18 years and over
People
65 worldwide
Run by
Dizal Pharmaceutical Co. Ltd.
See details and how to join2022-502959-54-00 · EU 2022-502959-54-00